February 14, 2024
Tumor antigen-specific CD8+ T cells are known to be important in antitumor immunity, but identifying them in patient samples is often a challenge. In order to study tumor antigen-specific CD8+ T cell as potential biomarkers of response, two groups, Pulliam and Jani et al. and Ryu et al., recently evaluated them in Merkel...
Adding a personalized neoantigen vaccine to checkpoint blockade keeps resected melanoma away in a phase IIb trial
February 7, 2024
Following surgical resection of high-risk cutaneous melanoma, patients are generally treated with checkpoint inhibitors to prevent tumor recurrence, but a high proportion of patients still recur within 5 years. In an effort to reduce these recurrence rates, Weber et al. evaluated the addition of adjuvant personalized neoantigen vaccines (mRNA-4157) in a phase IIb...